|
HS Code |
255378 |
| Chemical Name | (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester |
| Molecular Formula | C10H20N2O2 |
| Molecular Weight | 200.28 g/mol |
| Appearance | Typically a colorless to light yellow liquid or solid |
| Chirality | S - configuration at the chiral center |
| Solubility | Soluble in common organic solvents like dichloromethane, chloroform |
| Pka | The amine group has a pKa value around 9 - 11 |
| Stability | Stable under normal conditions, but sensitive to strong acids and bases |
As an accredited (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert - Butyl Ester in sealed chemical - grade vial. |
| Shipping | ( S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert - Butyl Ester is shipped with strict adherence to chemical transport regulations. Packed securely in appropriate containers, it's dispatched via reliable carriers to ensure safe and timely delivery. |
| Storage | (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could lead to degradation. Store in a well - ventilated area, separate from incompatible substances like strong oxidizing agents. |
Why does residual TFA in the Boc deprotection step trigger formation of a 0.8% dimer impurity in the downstream amidation for an autotaxin inhibitor intermediate?In the cGMP synthesis of a Phase II clinical‑stage autotaxin inhibitor (targeting idiopathic pulmonary fibrosis), (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester functions as the chiral amine input to construct the pyrrolidine‑amide pharmacophore. Production‑scale work at a contract manufacturing organization documented a recurring dimer by‑product when the free‑amine content fell below stoichiometric specifications, traced to residual trifluoroacetic acid carried forward from the tert‑butoxycarbonyl cleavage. The addition ratio of the liberated (S)-3‑aminomethylpyrrolidine to the heteroaryl carboxylic acid partner is maintained at 1.05 molar equivalents, with the 0.05 excess compensating for protonation by adventitious acid and for competitive hydrolysis of the activated ester. The downstream process sequence starts with dissolution of the N‑Boc intermediate in dichloromethane at 0–5 °C, followed by slow addition of 2.5 equivalents of trifluoroacetic acid; after 35–45 minutes of aging the mixture is concentrated under reduced pressure and the crude amine trifluoroacetate salt is crystallized from methyl tert‑butyl ether. In a dedicated Hastelloy C‑22 reactor equipped with an in‑line ReactIR probe, the isolated salt is neutralized with aqueous potassium carbonate and extracted into tetrahydrofuran where it is immediately combined with the carboxylic acid fragment pre‑activated with HATU (1.12 equiv) and diisopropylethylamine (3.0 equiv) at a jacket temperature setpoint of −2 °C; this thermal restriction suppresses racemization of the chiral centre and limits the dimer impurity measured by reversed‑phase HPLC to ≤ 0.12 area‑%. To further reduce dimer formation observed during pilot‑plant campaigns, the deprotection has been migrated to a continuous‑flow microreactor (PFA capillary, ID 0.8 mm, residence time 52 seconds) where the exotherm is rapidly dissipated, lifting the isolated yield from 88% to 94%. Industry‑compliance anchors include ICH Q7 Section 7.3 (critical intermediate controls), ICH Q3C options‑2 residual solvent limits (dichloromethane ≤ 600 ppm, tetrahydrofuran ≤ 720 ppm), and United States Pharmacopeia USP <232>/<233> elemental impurity verification, with chiral purity set at ≥ 99.5% ee on a Chiralpak IA‑3 column. The final terminal product is a free‑base oral autotaxin inhibitor drug substance suitable for tablet formulation.Production‑scale batches of an oral selective estrogen receptor degrader (SERD) intended for ER‑positive/HER2‑negative breast cancer rely on (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester as the source of a stereo‑defined ammonia‑equivalent handle during installation of the central pyrrolidine‑amide motif. Regulatory compliance for the intermediate is governed by ICH Q7 for active pharmaceutical ingredient starting materials and ICH M7 addendum for DNA‑reactive (mutagenic) impurity control, with daily monitoring of alkyl halide residues below the threshold of toxicological concern (1.5 µg/day) via gas chromatography–mass spectrometry. The addition ratio is dynamically controlled: the N‑Boc protecting group is removed using acetyl chloride (2.2 equiv) in anhydrous methanol (10 volumes) at 10 °C, and after precipitation of the hydrochloride salt with diisopropyl ether, the free amine is generated in‑situ with triethylamine (2.5 equiv) and immediately reacted with a pre‑formed mixed anhydride derived from the chiral acid fragment and isobutyl chloroformate (0.98–1.02 equivalents relative to the acid). Because the mixed anhydride hydrolyzes rapidly above −5 °C, the coupling is executed in a jacketed glass‑lined vessel with a jacket outlet temp of −12 °C, and the dosage rate of the activated acid is regulated by a Bronkhorst Mini CORI‑FLOW mass flow controller to maintain an internal temperature fluctuation of less than ±2 °C. The downstream manufacturing process then proceeds through aqueous work‑up (citric acid and sodium bicarbonate washes), solvent exchange into isopropyl acetate, and anti‑solvent crystallization with n‑heptane, affording the penultimate intermediate with a diastereomeric ratio > 99.7:0.3 determined by SFC on a Lux i‑Amylose‑1 column. Residual palladium, when a Suzuki‑Miyaura step has been employed on the acid fragment earlier, is controlled to ≤ 10 ppm per ICH Q3D Class 1B oral permitted daily exposure, verified by inductively coupled plasma mass spectrometry after microwave digestion. The terminal finished product is a film‑coated oral tablet containing the SERD active pharmaceutical ingredient, manufactured under EU GMP Part II for investigational medicinal products.Pyrrolidine‑thiourea bifunctional organocatalyst assembly via (S)-3‑aminomethyl‑pyrrolidine scaffoldWhen the laboratory‑scale production of a cinchona‑alkaloid‑derived hydrogen‑bonding catalyst is replaced by the more rigid (S)-3‑aminomethyl‑pyrrolidine framework, the resulting bifunctional thiourea exhibits improved turnover in asymmetric Michael additions to nitrostyrenes. The raw material is handled under an ISO 9001:2015 quality management system, with each lot accompanied by a certificate of analysis reporting 1H NMR and 13C NMR purity ≥ 98.0% and achiral HPLC area ≥ 97.5%. The stoichiometry for catalyst construction is straightforward: the N‑Boc protecting group is cleaved with 4.0 M hydrochloric acid in 1,4‑dioxane (3.0 equiv) over 2 hours at ambient temperature, and the resulting free diamine is reacted with 1.00 molar equivalent of 3,5‑bis(trifluoromethyl)phenyl isothiocyanate in dichloromethane to deliver the thiourea after flash chromatography. Downstream adaptation for fine‑chemical catalyst supply involves simple concentration and precipitation from n‑pentane, with no dedicated regulatory controls beyond standard material safety data sheet documentation. The end‑product is an off‑white powder used at 10 mol% loading in academic and pharmaceutical process‑development laboratories for the enantioselective construction of γ‑nitro carbonyl building blocks.When the Buchwald–Hartwig coupling of aryl bromides with the free amine derived from the tert‑butyl carbamate is run at 85 °C instead of 95 °C, palladium residue in the crude JAK inhibitor intermediate drops below 5 ppmFor a pre‑clinical selective Janus kinase inhibitor candidate requiring a (3S)-3‑(aminomethyl)pyrrolidine side chain, (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester serves as the pre‑protected chiral amine. Process analytical technology implemented on the 300 L glass‑lined vessel equipped with a retreat‑curve impeller showed that the exothermic oxidative addition step in the palladium‑catalyzed N‑arylation imposes a narrow thermal operating window. The formulation addition ratio fixes the aryl bromide at 1.00 equivalent, the Boc‑deprotected amine at 1.10 equivalents, palladium(II) acetate at 0.05 equivalents, and racemic BINAP at 0.065 equivalents, with sodium tert‑butoxide (1.4 equiv) as the base in degassed toluene (8 volumes). The reactor is first inertised with three vacuum‑nitrogen cycles, charged with the solids, and heated to an internal temperature of 85 ± 3 °C under a low‑flow nitrogen sweep; at this temperature the reaction completes within 8–10 hours while suppressing palladium nanoparticle aggregation, thereby enabling a post‑reaction treatment with powdered activated charcoal (0.5 wt% relative to theoretical product mass) to reduce soluble palladium below the 5 ppm target. Following filtration through a pad of Celite‑545 and aqueous work‑up with 5% N‑acetyl‑cysteine solution to chelate residual metals, the product is crystallized from methyl tert‑butyl ether as the N‑Boc intermediate. This intermediate routinely meets the ICH Q3D oral PDE for palladium (Class 1B, ≤ 100 µg/day) and nickel (Class 2A, ≤ 200 µg/day) when dosed at a projected tablet strength of 15 mg active moiety. The regulatory compliance framework for the stage relies on ICH Q7 Q7A guidance for registered intermediates and a site master file audited against 21 CFR Part 210 and 211. The terminal product type is a crystalline free‑base JAK inhibitor drug substance candidate stored at −20 °C under argon pending formulation into hydroxypropyl methylcellulose capsules for first‑in‑human studies. |
Competitive (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | (S)-Boc-3-aminomethyl | (±)-Boc-3-aminomethyl (Racemate) | (S)-Cbz-3-aminomethyl |
|---|---|---|---|
| CAS Registry Number | 199174-24-8 | 1049679-45-6 (representative lot) | 362488-73-9 |
| Physical State at 20°C | Low-melting solid / viscous oil | Crystalline solid (m.p. 42–48°C) | Colorless oil |
| Specific Rotation [α]D20 | −12° to −18° (c=1.0, MeOH) | 0° (within instrumental error) | −8° to −14° (c=1.0, MeOH) |
| Deprotection Method | TFA/CH₂Cl₂ or HCl/dioxane, 0–25°C | Identical to (S)-enantiomer | H₂, 10% Pd/C, EtOH, 1 atm |
| Orthogonal Stability | Labile to acid; stable to base and hydrogenolysis | Labile to acid; stable to base and hydrogenolysis | Stable to acid; labile to hydrogenolysis |
| Chiral HPLC RRT (IA column) | 1.00 | Two peaks at 1.00 and 1.15 | 0.92 (retention shift due to benzyl group) |
| Typical Application Window | Solution-phase peptide couplings, kinase inhibitors | Method development standard, achiral library syntheses | Sequences requiring acidic or oxidative stability |
| Test Parameter | Analytical Method | Acceptance Criterion |
|---|---|---|
| Appearance | Visual inspection (USP 〈1〉) | Colorless to pale yellow oil or waxy solid, free of particulate matter |
| Chemical Purity | RP-HPLC, C18, 210 nm (USP <621>) | ≥98.0 area% |
| Enantiomeric Excess | Chiral HPLC, CHIRALPAK IA, UV 210 nm | ≥99.0% |
| Water Content | Karl Fischer coulometry (USP <921>, Method Ic) | ≤0.50% w/w |
| Residual Solvents | Headspace GC-FID (USP <467>) | Ethanol ≤500 ppm, THF ≤720 ppm, CH2Cl2 ≤600 ppm |
| Specific Rotation | Polarimetry, 589 nm, 20°C | −10.0° to −20.0° (c=1.0, MeOH) |
| Heavy Metals | ICP-OES (USP <233>) | Pd ≤10 ppm, Fe ≤15 ppm |
| Storage Condition | — | Sealed under argon at −15°C to −25°C, protected from light and moisture |